Galapagos cleans closet of another 4 programs to make room for CAR-T ambitions

You’d be forgiven for thinking that Galapagos had already trimmed all the fact it could off its pipeline, but the Belgian biotech has managed to find another four early-stage programs worthy of being culled in favor of its CAR-T strategy.